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Abstract The aim of this study was to assess HBV DNA
suppression after 24 weeks of treatment with entecavir in
previously treated children with CHB. Thirty children aged
5–17 years (25 males and 5 females) with CHB were treated
with entecavir 0.5 or 1 mg daily. Twenty-two children were
HBeAg-positive, eight were HBeAg-negative, and in eight
HBV polymerase mutations were detected. After 24 weeks of
treatment, mean and median HBV DNA levels and ALT
activity were lower versus baseline, overall and in both
subgroups. The overall median HBV DNA level decreased
from 1.2 x 10
7 IU/mL to 3.3 x 10
2 IU/mL (p < 0.000004), in
HBeAg-positive from 7.8x10
7 IU/mL to 6.3x10
3 IU/mL
(p < 0.00004), and in HBeAg-negative from 2.5x10
4 IU/mL
to 5.01x10
1 IU/mL (p < 0.03). The serum HBV DNA
disappearance was observed in 7/8 (88%) HBeAg-negative
and in 5/22 (23%) HBeAg-positive patients. The overall
mean ALT activity decreased from 164+ 290 U/L to 34.1+
18.9 U/L (p < 0.000007), in HBeAg-positive from 214+326
U/L to 38.59+19.2 U/L (p < 0.000074), and in HBeAg-
negative from 27+14 U/L to 20+8 U/L (p <0 . 0 3 ) .T w e n t y -
four weeks of treatment with entecavir results in suppression
of HBV DNA in a substantial proportion of children
previously treated ineffectively with CHB.
Introduction
In the time of common anti-HBV vaccination, children at risk
forHBVinfectionincludethosewhowerenotvaccinated,had
an inadequate response to vaccination, were exposed prior to
being vaccinated, were born to HBV-infected mothers but did
not receive active/passive immunoprophylaxis or this immu-
noprophylaxis was ineffective [1].
Chronic hepatitis B in children is mostly asymptomatic,
but they are at risk for severe complications like liver
cirrhosis and hepatocellular carcinoma (HCC).
Individuals who acquire the virus vertically during
childbirth or at a young age are the priority for effective
treatment. The current goals of treatment are: suppression
of viral replication to undetectable HBV DNA levels, ALT
level normalisation, HBe/anti HBe seroconversion, an
improvement in liver histology and preventing liver
complications by reducing the risk of progressive liver
disease.
Anti-HBV therapies approved for adults include inter-
feron alpha, an immune modulator and nucleoside/nucleo-
tide analogues that suppress viral replication [2, 3].
Treatment options for children with chronic hepatitis B
are limited. In Poland, standard anti-HBV therapy in
children now includes only recombinant interferon.
The aim of this study was to assess the HBV DNA
suppression after 24 weeks of treatment with entecavir of
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Materials and methods
Thirty children with chronic hepatitis B, who did not
respond to previous anti-HBV therapy were included in
treatment with entecavir. There were 25 males and five
females in the group, aged 5–17 years (mean age 15.3±
2.34). Twenty-two children were HBeAg-positive and eight
were HBeAg-negative. Seven children had previously been
treated with recombinant interferon (IFN), two with
lamivudine (LAM), one with adefovir (ADV), 19 with
IFN and LAM, and one with IFN, LAM and ADV.
Baseline HBV DNA viral load was >10^7 IU/mL in 15
children, between 10^6 and 10^7 IU/mL in three patients,
between 10^5 and 10^6 in three, between 10^4 and
10^5 IU/mL in seven and between 10^3 and 10^4 IU/mL
in two children. In eight children, HBV polymerase
mutations L180M and M204V were detected, and L80I
and M204I in one.
All children had a liver biopsy and liver ultrasound as a
prerequisite to enrolment and treatment. Liver biopsy speci-
menswerescoredaccordingtothemodifiedScheuerscaleand
were assigned a grade for necroinflammation between 0 and 4
andastagebetween0and4forfibrosis[4]. No child had liver
disease assessed greater than grade 2, stage 2.
In the examined group there were no patients with
histological evidence of hepatocellular carcinoma or chron-
ic liver disease other than CHB. Patients co-infected with
hepatitis C virus or human immunodeficiency virus were
not eligible for treatment.
Children and adolescents included in the study received
entecavir in the dose 0.5 or 1 mg daily.
The protocol was approved by the ethics committee of
Collegium Medicum Nicolaus Copernicus University in
Bydgoszcz, Poland. Informed consent was provided in
writing by the legal guardian of each patient and each child
older than 12 years before treatment was initiated.
During treatment patients were required to return to the
clinic at regular intervals at which time blood samples were
obtained for determination of serum HBV DNA, HBeAg,
HBsAg, and ALT activity. A complete blood count was
performed at each clinic visit.
Serum HBV DNA was determined at baseline and at
week 24 by quantitative polymerase chain reaction assay
(COBAS® AmpliPrep/COBAS TaqMan® HBV Test, limit
of quantitation=55 IU/mL; limit of detection 12 IU/mL
[Roche Diagnostics]).
In 24 patients serum HBV DNAwas assessed at weeks 4
and 12 during therapy.
Safety was monitored at each clinic visit by means of
laboratory tests, physical examination and adverse events
reported by the patient or guardian.
Statistical analysis
Serum HBV DNA levels, ALT activity, grading and staging
were analysed by descriptive statistics. Means and standard
Table 1 Baseline characteristics of patients
Characteristic HBeAg-positive (n=22) HBeAg-negative (n=8) All patients (n=30)
Age (years), mean±SD (range) 15.3±2.68 15.3±1.04 15.3±2.34
Male : female 3 : 2 6 : 2 9 : 4
HBV DNA, IU/ml, mean±SD 8.1x10^7±9.7x10^7 3.5x10^4±2.9x10^4 6.1x10^7±9.1x10^7
Serum ALT (IU/l
a), mean±SD 214±326 27±14.04 164±290
Fibrosis stage, mean (range) 2 (1–2) 1.57 (0–2) 2 (0–2)
Necroinflammatory grade, mean (range) 2 (1–2) 1.86 (1–2) 2 (1–2)
aUpper limit of normal: females 31 IU/l; males 40 IU/l
Table 2 Serum HBV DNA (IU/mL) level and ALT activity after 24 weeks of treatment vs. baseline in examined patients
Measure Baseline After 24 weeks of treatment p (Wilcoxon’s test)
Mean±SD Median Mean±SD Median
Serum HBV DNA (IU/mL) 61088601±91363098 12000000 69547±223304 326 0.000004
Min 1000 Min 0.0000
Max 410000000 Max 1100000
ALT activity (U/L) 164±290 60 34.10±18.9 30 0.000007
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calculated for values collected at baseline and in week 24.
To compare those results in HBeAg positive and HBeAg
negative patients, the U Mann-Whitney’s and Wilcoxon’s
tests were used.
Results
The baseline characteristics of the patients are presented
in Table 1.
In all patients we observed the increased ALT activity
values during the 2 years prior to treatment, although ALT
within normal limits was recorded at the start of entecavir
treatment in eight patients. No child had severe liver disease
assessed as greater than grade 2, stage 2 on the pretreatment
liver biopsy but had at least grade 1 and/or stage 1 at baseline.
Mean baseline serum HBV DNA level and ALT activity
were statistically significantly lower in HBeAg-negative
patients in comparison to HBeAg-positive (p<0.0003 and
p<0.0006, respectively).
HBV DNA levels and ALT activity decreased in all
patients during treatment with entecavir.
After 24 weeks of treatment, mean and median HBV
DNA levels and ALT activity were lower than the baseline
value, overall and in the HBeAg-positive and HBeAg-
negative subgroups. The overall median HBV DNA level
decreased from 1.2 x 10
7 IU/mL at baseline to 3.3 x 10
2 IU/
mL after 24 weeks of treatment (p<0.000004). In HBeAg-
positive patients the median HBV DNA level decreased
from 7.8x10
7 IU/mL at baseline to 6.3x10
3 IU/mL (p<
0.00004), and in HBeAg-negative from 2.5x10
4 IU/mL to
5.0
1x10 IU/mL, respectively (p<0.03) (Tables 2, 3, 4).
Mean serum HBV DNA level and ALT activity after
24 weeks of treatment were statistically significantly lower
in HBeAg-negative patients in comparison to HBeAg-
positive (respectively,p <0.002 and p<0.005).
After 24 weeks of treatment serum HBV DNA was
undetectable in 12 patients: The serum HBV DNA
disappearance was observed in seven of the eight (88%)
HBeAg-negative patients, and in five of the 22 (23%)
HBeAg-positive. Among seven HBeAg negative patients
with undetectable HBV DNA after 24 weeks of therapy, six
were with normal ALT activity while one patient was with
increased ALT activity at baseline. In all five HBe-positive
patients with HBV DNA disappearance after 24 weeks of
entecavir therapy the baseline ALT activity was increased.
In six patients with HBV DNA disappearance, serum
HBV DNA was undetectable from the 5th week of
treatment. Among them there were five HBeAg-negative
and one HBeAg-positive patients at baseline. Until the 24th
week of therapy we did not observe HBe/anti-HBe
seroconversion in this and other patients who were
HBeAg-positive at baseline.
The overall mean ALT activity decreased from 164±290
U/L at the baseline to 34.1±18.9 U/L after 24 weeks of
entecavir therapy (p<0.000007). In HBeAg-positive
patients the mean ALT activity decreased from 214±326
U/L to 38.59±19.2 U/L (p<0.000074) and in HBeAg
negative patients from 27±14 U/L to 20±8 U/L (p<0.03),
respectively.
During the period analyzed we did not observe any
adverse events of entecavir therapy.
Discussion
Treatment of children with chronic hepatitis B seems to
be controversial. Some authors declare that most HBV
infected children will remain in the immune tolerant
Measure Baseline After 24 weeks of treatment p
Mean±SD Median Mean±SD Median
Serum HBV DNA
(IU/mL)
80514591±97425806 77500000 91654±253703 6325 0.000040
Min 1000 Min 0.0000
Max 410000000 Max 1100000
ALT activity (U/L) 214±326 75 38.59±19.2 31 0.000074
Table 3 Serum HBV DNA and
ALT activity after 24 weeks of
treatment vs. baseline in
HBeAg- positive patients
Measure Baseline After 24 weeks of treatment p
Mean±SD Median Mean±SD Median
Serum HBV DNA
(IU/mL)
35491±29886 25000 69±51 50 0.027709
Min 6840 Min 50
Max 96200 Max 184
ALT activity (U/L) 27±14 21 20±8 19 0.027709
Table 4 Serum HBV DNA and
ALT activity after 24 weeks of
treatment vs. baseline in
HBeAg- negative patients
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this phase of HBV infection is not indicated [5]. Although
most children with chronic hepatitis B are asymptomatic and
severe liver disease during childhood is rare, they are at risk
for developing serious complications, including liver cirrho-
sis and HCC.
The results of this study demonstrate that a 24-week
course of entecavir therapy in children and adolescents can
produce suppression of HBV DNA replication in HBeAg-
positive and HBeAg-negative individuals, previously treated
ineffectively with anti-HBV. After 24 weeks of entecavir
treatment the serum HBV DNA decreased in all treated
patients. The serum HBV DNA disappearance was observed
in seven of the eight (88%) HBeAg-negative patients, and in
five of the 22 (23%) HBeAg-positive.
These results are clinically significant because HBV DNA
levelscorrelate withanincreasedriskofliverdisease.Thereis
a linear relationship between the serum concentration of HBV
DNA and the long-term risk of cirrhosis and hepatocellular
carcinoma in patients with CHB [6–8]. Effective treatment is
particularly important in children with CHB, because the
virus cannot be eradicated and, as a result, complications can
evolve over many decades in these individuals.
In five of the six patients with HBV DNA disappear-
ance after 24 weeks of therapy, undetectable levels of
HBV DNA were observed after the initial 4 weeks of
therapy (RVR). It seems that early disappearance of HBV
viremia may by a predictor of beneficial treatment
response. Sustained suppression of HBV DNA replica-
tion results in histological improvement, normalization of
ALT levels and, in some patients with HBeAg-positive
disease, seroconversion to an anti-HBe state [9–11].
Treatment with entecavir decreasing HBV DNA replica-
tion induced the biochemical and histological improve-
ment of liver disease in adults [12, 13].
In the examined patients, treatment with entecavir was
well tolerated. There were no unknown safety issues
emerging in this population and the safety profile was
similar to that seen in adult populations. We did not observe
ALT flares and entecavir resistance mutations.
In conclusion, the results of this pilot study show that
24 weeks of treatment with entecavir results in suppression
of HBV DNA in a substantial proportion of children
previously treated ineffectively with CHB. Larger and
longer trials are now required to better define the magnitude
of the benefit in this population.
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